{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059009","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2026-05-12T11:35:31+00:00","discovered_at":"2026-05-12T11:40:00.383958+00:00","generated_at":"2026-05-12T11:41:28.092341+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sagimet Q1 net loss $10.7M; $175M April financing; Phase 3 acne trial H2 2026","bullets":["Net loss $10.7M for Q1 2026 vs $18.2M in Q1 2025; R&D expense $7.0M (down from $15.3M YoY).","Cash, cash equivalents and marketable securities $104.5M as of March 31, 2026; expects funding through 2028.","Completed $175M equity financing in April 2026 (29.2M shares at $6.00) to fund acne programs.","Plans to initiate U.S. Phase 3 trial of denifanstat in moderate-to-severe acne in second half 2026.","Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned after completion subject to regulatory consultation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059009","json":"https://secwatch.observer/filing/0001104659-26-059009.json","markdown":"https://secwatch.observer/filing/0001104659-26-059009.md","text":"https://secwatch.observer/filing/0001104659-26-059009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/0001104659-26-059009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:41:28.092341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79a89f6e8daf4e07dcfd96286051de9293e19db7","claim":"Sagimet Biosciences Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026, was $10.7 million.","evidence_excerpt":"Sagimet Biosciences Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/0001104659-26-059009-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2026, was $10.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}